[144] BeOne Medicines Ltd. American SEC Filing

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) filed a Form 144 disclosing a proposed sale of 10,338 ADS on NASDAQ with an aggregate market value of $2,978,377.80. The filing shows those ADS were acquired partly by an exercise of stock options (9,226 ADS, cash paid on 08/13/2025) and partly as restricted stock units (1,112 ADS on 06/05/2025). The notice lists 54,564,278 shares outstanding, and the proposed block represents a very small portion of outstanding shares.

The filing also discloses recent sales by the same seller over the past three months: 2,042 common shares sold on 07/30/2025, 06/16/2025 and 06/06/2025 for combined gross proceeds of $571,975.61. This Form 144 is a regulatory notice of intent to sell and records the means of acquisition and prior dispositions.

Insights

Securities Analyst

TL;DR: Small insider sale disclosed: 10,338 ADS (~0.019% of outstanding) valued at $2.98M, acquired via option exercise and RSUs.

The filing documents a proposed sale under Rule 144 of 10,338 ADS with an aggregate market value of $2,978,377.80. Given the issuer's stated 54,564,278 shares outstanding, the block is immaterial as a percentage of the total equity. The ADS were acquired primarily through an option exercise and RSU vesting, which are routine forms of executive compensation realization. Recent small dispositions totaling 2,042 common shares for $571,975.61 are recorded, indicating ongoing monetization but not a large-scale exit. From a market-impact perspective this filing is informational rather than material.

Corporate Governance Expert

TL;DR: The disclosure meets compliance norms; insider sales were from compensation events, not shown as forced or unusual.

The Form 144 clearly identifies acquisition dates and the nature of acquisition (option exercise and RSUs), and states payment method where applicable (cash). This transparency supports regulatory compliance and helps shareholders track insider liquidity. The scale of the proposed sale relative to the issuer's reported outstanding shares is negligible, and prior three-month sales are modest. There is no explicit indication in the filing of any material, nonpublic adverse information or unusual trading arrangements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10338	2978377.80	54564278	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	08/13/2025	Exercise of Stock Options	Issuer			9226	08/13/2025	Cash
ADS	06/05/2025	Restricted Stock Units	Issuer			1112	06/05/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	Common	07/30/2025	920	280232.74
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	Common	06/16/2025	422	112463.00
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	Common	06/06/2025	700	179279.87

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BeOne Medicines (ONC) disclose in the Form 144?

The Form 144 discloses a proposed sale of 10,338 ADS valued at $2,978,377.80, acquired via option exercise and RSUs, to be sold on NASDAQ.

How were the ADS being sold acquired according to the filing?

The filing shows 9,226 ADS were acquired by exercise of stock options (paid in cash on 08/13/2025) and 1,112 ADS were received as restricted stock units on 06/05/2025.

What portion of outstanding shares does the proposed sale represent for ONC?

The filing reports 54,564,278 shares outstanding; the proposed 10,338 ADS represent a very small portion of that total (approximately 0.019% by count).

Did the filer sell any ONC securities in the past three months?

Yes. The filer sold 2,042 common shares on 07/30/2025, 06/16/2025 and 06/06/2025 for combined gross proceeds of $571,975.61.

Where will the proposed ADS sale occur?

The filing lists the NASDAQ exchange and identifies Morgan Stanley Smith Barney LLC as the broker handling the transaction.